AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

LEGN · NASDAQ · Biotechnology

Legend Biotech (ADR) (LEGN)

Commercializes CARVYKTI while developing next-generation CAR-T therapies.

$18.64

vs last close+0.11 (+0.59%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	96	79	94	187	160	187	195	255	272	306	305	388
Cost of revenue	49	32	55	50	55	74	71	98	115	123	176	137
Gross profit	47	47	39	136	105	113	124	157	157	183	129	250
	140	167	157	178	175	187	174	179	200	204	179	192
Research & development	96	106	101	113	96	104	102	98	113	101	86	96
	44	62	56	65	80	83	72	81	87	101	90	96
Selling & marketing	0	34	24	30	44	49	41	48	53	64	50	63
General & administrative	0	29	32	35	35	34	31	33	35	37	40	33
Other expenses	0	−1	0	0	0	−1	0	0	0	1	3	0
Operating income	−93	−120	−118	−42	−70	−74	−51	−22	−43	−21	−50	58
	30	−27	58	24	−51	115	−48	−103	4	1	−3	−2
Interest income	18	17	14	17	17	14	12	10	10	8	7	0
Interest expense	6	6	5	5	6	5	5	5	6	5	6	0
Other non-operating income	−36	21	−64	−29	45	−120	43	98	−4	−6	−2	0
Income before tax	−62	−147	−60	−18	−121	41	−99	−125	−39	−20	−53	56
Income tax expense	0	−2	0	0	4	14	2	1	1	11	1	22
Net income from continuing operations	−62	−145	−60	−18	−125	26	−101	−125	−40	−31	−54	33
Net income	−62	−145	−60	−18	−125	26	−101	−125	−40	−31	−54	33
EPS, basic	−$0.34	−$0.80	−$0.33	−$0.10	−$0.68	$0.14	−$0.55	−$0.68	−$0.21	−$0.17	−$0.30	$0.18
EPS, diluted	−$0.34	−$0.80	−$0.33	−$0.10	−$0.68	$0.14	−$0.55	−$0.68	−$0.22	−$0.17	−$0.30	$0.18
Weighted average shares, basic	182	182	182	183	183	183	184	184	180	185	185	187
Weighted average shares, diluted	182	182	182	183	183	183	184	184	185	185	185	194
EBITDA	−52	−136	−49	−7	−110	52	−89	−114	−33	−2	−32	60
Depreciation & amortization	5	5	6	5	5	7	5	6	6	12	16	2
EBIT	−57	−141	−54	−12	−115	46	−94	−120	−39	−14	−48	58